Nov 22, 2021 8:30am EST Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Nov 09, 2021 4:05pm EST Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
Nov 04, 2021 8:30am EDT Achieve Life Sciences Announces Participation in November Investor Conferences
Nov 02, 2021 8:30am EDT Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
Oct 26, 2021 8:30am EDT Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
Sep 14, 2021 5:30am EDT Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
Aug 13, 2021 5:30am EDT Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
Aug 11, 2021 4:05pm EDT Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update